Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

39.25
+0.04000.10%
Post-market: 39.250.00000.00%19:25 EDT
Volume:2.19M
Turnover:85.48M
Market Cap:10.57B
PE:18.90
High:39.60
Open:39.33
Low:38.62
Close:39.21
52wk High:49.62
52wk Low:27.86
Shares:269.20M
Float Shares:231.84M
Volume Ratio:0.91
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.08
EPS(LYR):1.80
ROE:29.00%
ROA:17.24%
PB:5.20
PE(LYR):21.84

Loading ...

Exelixis: Cabometyx Reduced Risk of Disease Progression or Death by 81% Versus Placebo in Patients With Advanced Lung or Thymic Neuroendocrine Tumors

THOMSON REUTERS
·
6 hours ago

Exelixis Announces Results From Subgroup Analysis of Cabinet Phase 3 Pivotal Trial Evaluating Cabometyx® (Cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at Esmo 2025

THOMSON REUTERS
·
6 hours ago

Exelixis Reports CABOMETYX Cuts Progression Risk by 81% in Advanced Lung and Thymic NETs

Reuters
·
6 hours ago

Goldman Sachs Reaffirms Their Buy Rating on Exelixis (EXEL)

TIPRANKS
·
Oct 16

Truist Financial Remains a Buy on Exelixis (EXEL)

TIPRANKS
·
Oct 14

Exelixis Hold Rating: Modest Sales Forecasts and Competitive Challenges Amid Upcoming STELLAR-303 Data

TIPRANKS
·
Oct 14

Exelixis (EXEL): Analyst Upgrades and Value Signals Put Stock’s Valuation in Focus

Simply Wall St.
·
Oct 12

RBC Capital Remains a Hold on Exelixis (EXEL)

TIPRANKS
·
Oct 10

Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Exelixis (EXEL) and Sanofi (OtherSNYNF)

TIPRANKS
·
Oct 09

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.
·
Sep 24

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Healthcare Services (HCSG)

TIPRANKS
·
Sep 22

Novo Nordisk, Grab, Vistra, Exelixis, Dropbox: Trending by Analysts

TIPRANKS
·
Sep 20

Exelixis (EXEL) Has a New Rating from Barclays

TIPRANKS
·
Sep 19

Exelixis Inc. : Morgan Stanley Raises Target Price to $50.00 From $46.00

THOMSON REUTERS
·
Sep 17

Exelixis Initiated at Equal-Weight by Barclays

Dow Jones
·
Sep 17

Exelixis initiated with a Buy at Goldman Sachs

TIPRANKS
·
Sep 17

Exelixis assumed with an Equal Weight at Barclays

TIPRANKS
·
Sep 17

Adagene expands SAFEbody collaboration, license agreement with Exelixis

TIPRANKS
·
Sep 16

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

GlobeNewswire
·
Sep 16

Exelixis Announces Appointment of Dana T. Aftab, Ph.d. as Executive Vice President, Research and Development

THOMSON REUTERS
·
Aug 30